Actively Recruiting

Age: 18Years +
All Genders
NCT06993220

Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients

Led by Consorci Sanitari Integral · Updated on 2025-07-18

500

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. While this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). The aim of the study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. Additionally, the analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.

CONDITIONS

Official Title

Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 65 18 years
  • Hospitalized for new onset or worsening heart failure
  • Symptoms classified as New York Heart Association class III or IV
  • Clinical or imaging signs of volume overload such as pulmonary congestion, pitting edema, or jugular venous distension
  • Elevated NT-proBNP levels within 24 hours of admission based on age-specific cutoffs
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Known diagnosis of septicemia
  • Glomerular filtration rate less than 15 ml/min
  • Life expectancy less than 6 months
  • Active myocarditis
  • Heart transplant recipients
  • Patients with ventricular assist devices
  • Congenital heart diseases
  • Moderate-to-severe liver disease (Child-Pugh B-C)
  • Patients not followed by the Heart Failure Unit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Complex Hospitalari Universitari Moisès Broggi

Sant Joan Despí, Barcelona, Spain, 08970

Actively Recruiting

Loading map...

Research Team

G

Giosafat Spitaleri, M.D.

CONTACT

R

Roman Freixa, M.D., Ph.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here